Myelodysplastic Syndromes (MDS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Myelodysplastic Syndromes (MDS) Market Outlook
Thelansis’s “Myelodysplastic Syndromes
(MDS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast
Report – 2024 To 2034" covers disease overview, epidemiology, drug
utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Myelodysplastic Syndromes (MDS)
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
Myelodysplastic
Syndromes (MDS) Overview
Myelodysplastic
syndrome (MDS) comprises a group of myeloid hematological disorders
distinguished by reduced blood cell counts, abnormalities in the bone marrow,
and a significant risk of evolving into acute myeloid leukemia (AML). Clinical
manifestations primarily result from low blood cell counts, predominantly
anemia, leading to fatigue, shortness of breath, and potentially angina. Less
frequently, MDS may manifest as thrombocytopenia, resulting in spontaneous
bleeding or neutropenia, making individuals susceptible to bacterial or, in
rarer cases, fungal infections. The underlying cause remains unknown in 80% of
cases. In the remaining 20%, it may be attributed to acquired factors such as
prior chemotherapy or radiation therapy, occupational exposure to benzene
derivatives or ionizing radiation, or inherited factors, including gene
mutations mainly involving DDX41, GATA2, RUNX, and telomerase genes, or DNA
instability (notably seen in Fanconi anemia patients who are prone to
developing MDS).
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment